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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To review the effects of HIV prevention advice for people with SMI.
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B A C K G R O U N D
Description of the condition
The definition of severe mental illness with the widest consensus
is that of the US National Institute of Mental Health (NIMH)
(Schinnar 1990) and is based on diagnosis, duration and disabil-
ity (NIMH 1987). People with serious mental illness (SMI) have
conditions such as schizophrenia or bipolar disorder, over a pro-
tracted period of time resulting in erosion of functioning in day
to day life. A European survey put the total population-based an-
nual prevalence of serious mental illness at approximately two per
thousand (Ruggeri 2000). Evidence suggests that those with SMI
have rates of HIV infection which are higher than expected in the
general population in the same demographic area (Hughes 2009).
The current prevalence rate of HIV infection for the general pop-
ulation in North America is 0.3%, which is marginally lower than
Europe (prevalence 0.4% - UNAIDS 2010). In contrast, studies
from the USA report prevalence rates of between 9% and 19%,
while in Europe five percent prevalence rates have been reported
for people with seriousmental illness (Cournos 1991;Grassi 1999;
Susser 1993). Despite this higher than expected prevalence, UK
national strategies around sexual health and HIV prevention do
not state that people with SMI are a high risk group. However, a
significant proportion in this group are sexually active and engage
in HIV-risk behaviours including having multiple sexual partners,
infrequent use of condoms and trading sex for money or drugs
(Rosenberg 2001). Additionally, during relapse, symptoms of SMI
may lead people to engage in practices they would not engage in
if functioning at their optimum level (Carey 2004).
Description of the intervention
HIV health advice can take many forms, depending on environ-
mental and socioeconomic factors. Advice is the active provision
of preventative information; it has an educative component and is
delivered in a gentle non-patronising manner (Stott 1990). There-
fore HIV health advice could be defined as any advice about HIV
health from a healthcare profession.
How the intervention might work
Advice fromahealthcare professional canhave a positive impact on
behaviour (Kreuter 2000; Russell 1979) and may motivate people
to seek further support and treatment (Sutherland 2003). Given
the evidence of increased rates of potentially preventable health
problems in people with serious mental illness (Cournos 2005;
Dixon 1999; Robson 2007), and the suggestion that methodolog-
ically robust, healthy living interventions give “promising out-
comes” in people with schizophrenia (Bradshaw 2005), we believe
that appropriate HIV health advice could improve the quality of
life and increase life expectancy for sufferers of serious mental ill-
ness. HIV healthcare advice from a healthcare professional may
encourage those with serious mental illness to be sexually absti-
nent, delay the initiation of sexual activity, decrease the numbers
of sexual partners, use condoms consistently and correctly if they
are sexually active and engage in harm reduction and needle ex-
change programmes.
Why it is important to do this review
People with SMI are some of the most vulnerable and socially ex-
cluded members of society; the same could be said for those with
HIV. Therefore, the combination of both debilitating illnesses
could have a profound social, psychological and economic impact
on individuals, their families and friends (Hughes 2009). It has
been identified that fewer than one in five people at risk of HIV
currently have access to infection prevention (The Global HIV
Prevention Working Group 2006). Given the effects of SMI and
the difficulties this population have in accessing general healthcare
advice (Tosh 2010), it is important that appropriate targeted ad-
vice is given to this group. It is important to complete this review
because there is no cure or vaccination for HIV; the only way to
prevent infection is by the adoption of safer sexual and injection
behaviours. We are not aware of any systematic review which com-
pares HIV advice-giving interventions to standard care for people
with SMI.
O B J E C T I V E S
To review the effects of HIV prevention advice for people with
SMI.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will consider all relevant randomised controlled trials (RCTs),
and economic evaluations conducted alongside included RCTs.
We will exclude quasi-randomised studies, such as those allocat-
ing by using alternate days of the week. When we encounter trials
described in some way so as to suggest or imply that the study was
randomised and where the demographic details of each group’s
participants are similar, we will include them and undertake sen-
sitivity analysis to evaluate the effect of the presence or absence of
these data.
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Types of participants
Wewill require that amajority of participants should be within the
age range 18 to 65 years and suffering from SMI, preferably as de-
fined by National Institute of Mental Health (NIMH 1987), but
in the absence of that, from diagnosed illness such as schizophre-
nia, schizophrenia-like disorders, bipolar disorder, or serious af-
fective disorders. If the trials include participants with a range of
serious mental illnesses we will include them if the majority have
schizophrenia, we will not include trials that only randomise peo-
ple with bipoloar or serious affective disorders. We will not con-
sider substance abuse to be SMI in its own right, however we do
feel that studies should remain eligible if they deal with people
with dual diagnoses, i.e. those with SMI plus substance abuse. We
will not include studies focusing on dementia, personality disorder
andmental retardation, as they are not covered by our definition of
SMI. Despite the fact that personality disorder is now included in
theNIMH definition we plan to exclude it from this review on the
basis that the diagnosis of personality disorders has low interrater
reliability (Zimmerman 1994); the duration of treatment can be
assessed much more precisely than duration of illness (Schinnar
1990); insufficient information is given on how to operationalise
the disability criterion in both the original NIMH (NIMH 1987)
definition and in the further work of Schinnar 1990.
Types of interventions
1. HIV prevention advice
We have found it difficult to find a useful definition of ‘advice’.
In the context of this review we will define ‘advice’ as preventative
information (Greenlund 2002) or counsel (OED) that leaves the
recipient to make the final decision. Advice may be directional but
not paternalistic in its delivery. It is not a programmed or training
approach, focusing on the acquisition of knowledge, skills and
competencies as a result of formal teaching sessions. The effects
of programmes and/or training approaches for HIV prevention in
people with SMI will not be considered in this review, they will
be considered in a future review.
2. Standard care
Care in which HIV advice is not specifically emphasised above
and beyond care that would be expected for people suffering from
SMI.
Types of outcome measures
For the purposes of this review we will divide outcomes into four
time periods: i. immediate (within one week); ii. short term (one
week to six months); iii. medium term (six months to one year);
and iv. long term (more than one year).
Primary outcomes
1. HIV infection (any time period)
2. Risk taking behaviour (short-term)
2.1 Unprotected sex
2.2 Sexual promiscuity
2.3 Sharing needles for drug use
Secondary outcomes
1. Adverse events
1.1 Number of participants with at least one adverse effect
1.2 Clinically important specific adverse events (cardiac events,
death, movement disorders, prolactin increase and associated ef-
fects, weight gain, effects on white blood cell count)
1.3 Average endpoint specific adverse events score
1.4 Average change in specific adverse events score
1.5 Death - natural or suicide
2. Service use
2.1 Hospital admission
2.2 Emergency medical treatment
2.3 Use of emergency services
3. Financial dependency
3.1 Claiming unemployment benefit
3.2 Claiming financial assistance because of a physical disability
4. Social
4.1 Unemployment
4.2 Social isolation as a result of preventable incapacity
4.3 Increased burden to caregivers
5. Quality of life
5.1 Loss of independence
5.2 Loss of activities of daily living (ADL) skills
5.3 Loss of earnings
5.4 Loss of social status
5.5 Healthy days
6. Economic
6.1 Increased costs of health care
6.2 Days off sick from work
6.3 Reduced contribution to society
6.4 Family claiming care allowance
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7. Leaving the study early (any reason, adverse events,
inefficacy of treatment)
8. Global state
8.1 Clinically important change in global state (as defined by in-
dividual studies)
8.2 Relapse (as defined by the individual studies)
9. Mental state (with particular reference to the positive and
negative symptoms of schizophrenia)
9.1 Clinically important change in general mental state score
9.2 Average endpoint general mental score
9.3 Average change in general mental state score
9.4 Clinically important change in specific symptoms (positive
symptoms of schizophrenia, negative symptoms of schizophrenia)
9.5 Average endpoint specific symptom score
9.6 Average change in specific symptom score
10. Risk taking behaviour
10.1 Unprotected sex (not short-term)
10.2 Sexual promiscuity (not short-term)
10.3 Sharing needles for drug use (not short-term)
10.4 STI incidences
10.5 Knowledge of HIV transmission routes
11. Health behaviours
11.1 Behavioural intentions
11.2 Behavioural intentions re safe needle practices
Search methods for identification of studies
Electronic searches
1. Cochrane Schizophrenia Group Trials Register
We will search the register using the phrase:
[(*physical* or *cardio* or *metabolic* or *weight* or *HIV* or
*AIDS* or *Tobacc* or *Smok* or *sex* or *medical* or *dental*
or *alcohol* or *oral* or *vision* or *sight*or *hearing* or *nutri-
tion* or *advice* or *monitor* in title of REFERENCES) AND
(*education* OR *health promot* OR *preventi* OR *motivate*
or *advice* or *monitor* in interventions of STUDY)]
This register is compiled by systematic searches ofmajor databases,
handsearches and conference proceedings (see group module).
Searching other resources
1. Reference searching
We will inspect the references of all identified studies for other
relevant studies.
2. Personal contact
We will contact the first author of each included study for infor-
mation regarding unpublished trials.
Data collection and analysis
Selection of studies
Two review authors (NW, AC) will screen the results of the elec-
tronic search. NW will inspect all abstracts of studies identified
through screening and identify potentially relevant reports. Once
identified, to ensure reliability, GT and AA will inspect a random
sample of these abstracts, comprising 10% of the total. Where
disagreement occurs, we will resolve this by discussion, and where
there is still doubt, we will acquire the full article for further in-
spection. We will then request the full articles of relevant reports
for reassessment and carefully inspect them for a final decision on
inclusion (see Criteria for considering studies for this review). In
turn NW and AC will inspect all full reports and independently
decide whether theymeet inclusion criteria.Wewill not be blinded
to the names of the authors, institutions or journal of publica-
tion. Where difficulties or disputes arise, we will ask author GT
for help; if it is impossible to decide, we will add these studies to
those awaiting assessment and contact the authors of the papers
for clarification.
Data extraction and management
1. Extraction
Authors NW and AC will independently extract data from in-
cluded studies. Again, wewill discuss any disagreement, document
our decisions and, if necessary, we will contact the authors of stud-
ies for clarification. We will extract data presented only in graphs
and figures whenever possible, but we will include such data only
if two authors independently reach the same result. We will at-
tempt to contact authors through an open-ended request in order
to obtain any missing information or for clarification whenever
necessary. Where possible, we will extract data relevant to each
component centre of multi-centre studies separately.
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2. Management
2.1 Forms
NW and AC will extract data onto standard, simple forms.
2.2 Data from multi-centre trials
Where possible the authors will verify independently calculated
centre data against original trial reports.
3. Scale-derived data
We will include continuous data from rating scales only if:
a. the psychometric properties of the measuring instrument have
been described in a peer-reviewed journal (Marshall 2000); and
b. the measuring instrument has not been written or modified by
one of the trialists for that particular trial.
Ideally, the measuring instrument should either be i. a self-report
or ii. completed by an independent rater or relative (not the ther-
apist).
We realise that this is not often reported clearly, but we will note
if this is the case or not in ’Description of studies’.
4. Endpoint versus change data
We prefer to use scale endpoint data, which typically cannot have
negative values and are easier to interpret from a clinical point of
view. Change data are often not ordinal and are very problematic
to interpret. If endpoint data are unavailable, we will use change
data.
5. Skewed data
Continuous data on clinical and social outcomes are often not
normally distributed. To avoid the pitfall of applying paramet-
ric tests to non-parametric data, we aim to apply the following
standards to all data before inclusion: (a) standard deviations and
means are reported in the paper or obtainable from the authors;
(b) when a scale starts from the finite number zero, the standard
deviation, when multiplied by two, is less than the mean (as oth-
erwise the mean is unlikely to be an appropriate measure of the
centre of the distribution, (Altman 1996); (c) if a scale starts from
a positive value (such as PANSS which can have values from 30 to
210), we will modify the calculation described above to take the
scale starting point into account. In these cases skew is present if
2SD>(S-S min), where S is the mean score and S min is the mini-
mum score. Endpoint scores on scales often have a finite start and
end point and these rules can be applied. When continuous data
are presented on a scale which includes a possibility of negative
values (such as change data), it is difficult to tell whether data are
skewed or not. We will enter skewed data from studies of fewer
than 200 participants in additional tables rather than into an anal-
ysis. Skewed data pose less of a problem when looking at means if
the sample size is large, and we will enter skewed data from large
sample sizes into syntheses.
6. Common measure
To facilitate comparison between trials, we intend to convert vari-
ables that can be reported in different metrics, such as days in hos-
pital (mean days per year, per week or per month) to a common
metric (e.g. mean days per month).
7. Conversion of continuous to binary
Where possible, we will attempt to convert outcome measures
to dichotomous data. This could be done by identifying cut-off
points on rating scales and dividing participants accordingly into
’clinically improved’ or ’not clinically improved’.We will generally
assume that if there has been a 50% reduction in a scale-derived
score such as the Brief Psychiatric Rating Scale (Overall 1962) or
the Positive and Negative Syndrome Scale (Kay 1986; Kay 1987),
this could be considered as a clinically significant response (Leucht
2005; Leucht 2005a). If data based on these thresholds are not
available, we will use the primary cut-off presented by the original
authors.
8. Direction of graphs
Where possible, we will enter data in such a way that the area to
the left of the line of no effect indicates a favourable outcome for
HIV advice.
9. Summary of findings table
We anticipate including the following outcomes in a summary of
finding table:
9.1 HIV infection (measured by CD4+ count and viral load)
- Not using a condom
- Number of casual sexual partners
- Prevelance of needle sharing
9.2 Quality of life
- Loss of independence
- Loss of activities of daily living (ADL) skills
- Loss of social status
- Healthy days
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9.3 Adverse events
- Clinically important specific adverse effects (cardiac effects,
death, movement disorders, prolactin increase and associated ef-
fects, weight gain, effects on white blood cell count)
9.4 Service use
- Hospital admission
9.5 Leaving the study early
- Increased costs of health care
9.6 Sexual health practices
- STI incidences - knowledge of HIV transmission
9.7 Safer needle practices
- Attitude towards safer needle practice
- Behavioural intentions and safer needle intention
Assessment of risk of bias in included studies
Again review authors NW and AC will work independently to
assess risk of bias by using criteria described in the Cochrane Col-
laboration Handbook (Higgins 2011) to assess trial quality. This
set of criteria is based on evidence of associations between over-
estimate of effect and high risk of bias of the article such as se-
quence generation, allocation concealment, blinding, incomplete
outcome data and selective reporting.
If the raters disagree, the final rating will be made by consensus,
with the involvement of another member of the review group.
Where inadequate details of randomisation and other characteris-
tics of trials are provided, authors of the studies will be contacted
in order to obtain further information. Non-concurrence in qual-
ity assessment will be reported, but if disputes arise as to which
category a trial is to be allocated, again, we will resolve by discus-
sion.
The level of risk of bias will be noted in both the text of the review
and in the Summary of findings table 1.
Measures of treatment effect
1. Binary data
For binary outcomes we will calculate a standard estimation of
the fixed-effect risk ratio (RR) and its 95% confidence interval
(CI). It has been shown that RR is more intuitive (Boissel 1999)
than odds ratios and that odds ratios tend to be interpreted as
RR by clinicians Deeks 2000). Within the Summary of Findings
table we will assume for calculation of the low risk groups that the
lowest control risk applies to all data. We will do the same for the
assumption of the highest risk groups. We will use the Summary
of Findings table to calculate absolute risk reduction for primary
outcomes.
2. Continuous data
For continuous outcomes we will estimate a random-effects mean
difference (MD) between groups. We prefer not to calculate effect
size measures (standardised mean difference - SMD). However, in
the case of where scales were of such similarity to allow, presuming
there was a small difference in measurement, we will calculate it
and, whenever possible, transform the effect back to the units of
one or more of the specific instruments.
Unit of analysis issues
1. Cluster trials
Studies increasingly employ ’cluster randomisation’ (such as ran-
domisation by clinician or practice) but analysis and pooling of
clustered data pose problems. Firstly, authors often fail to account
for intra class correlation in clustered studies, leading to a ’unit
of analysis’ error (Divine 1992) whereby P values are spuriously
low, confidence intervals unduly narrow and statistical significance
overestimated. This causes type I errors (Bland 1997; Gulliford
1999).
Where clustering is not accounted for in primary studies, we will
present data in a table, with a (*) symbol to indicate the presence
of a probable unit of analysis error. In subsequent versions of this
reviewwewill seek to contact first authors of studies to obtain intra
class correlation co-efficient of their clustered data and to adjust for
this by using acceptedmethods (Gulliford 1999).Where clustering
has been incorporated into the analysis of primary studies, we will
present these data as if from a non-cluster randomised study, but
adjusted for the clustering effect.
We have sought statistical advice and have been advised that the
binary data as presented in a report should be divided by a ’design
effect’. This is calculated using the mean number of participants
per cluster (m) and the intra class correlation co-efficient (ICC)
[Design effect = 1+(m-1)*ICC] (Donner 2002). If the ICChas not
been reported, we will assume it to be 0.1 (Ukoumunne 1999).
If cluster studies have been appropriately analysed, taking into ac-
count intra class correlation co-efficient and relevant data docu-
mented in the report, synthesis with other studies may be possible
using the generic inverse variance technique.
2. Cross-over trials
Amajor concern of cross-over trials is the carryover effect. It occurs
if an effect (e.g. pharmacological, physiological or psychological) of
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the treatment in the first phase is carried over to the second phase.
As a consequence, on entry to the second phase the participants
can differ systematically from their initial state despite a wash-out
phase. For the same reason, cross-over trials are not appropriate
if the condition of interest is unstable (Elbourne 2002). As both
effects are very likely in severe mental illness, we will only use data
from the first phase of cross-over studies.
3. Studies with multiple treatment groups
Where a study involves more than two treatment arms, if relevant,
we will present the additional treatment arms in comparisons.
Where the additional treatment arms are not relevant, we will not
reproduce these data.
Dealing with missing data
1. Overall loss of credibility
At some degree of loss of follow-up, data must lose credibility (Xia
2009). For any particular outcome should less than 50% of data
be unaccounted, we will not reproduce these data or use them
within analyses. If, however, more than 50% of those in one arm
of a study are lost, but the total loss is less than 50%, we will mark
such data with ’*’ to indicate that such a result may well be prone
to bias.
2. Binary
In the case where attrition for a binary outcome is between 0 and
50% andwhere these data are not clearly described, wewill present
data on a ’once-randomised-always-analyse’ basis (an intention-to-
treat analysis). We will assume those lost to follow-up to have the
same rates of negative outcome as those who completed, with the
exception of the outcome of death.We will undertake a sensitivity
analysis testing how prone the primary outcomes are to change
when ’completer’ data only are compared to the intention-to-treat
analysis using the above assumption.
3. Continuous
3.1 Attrition
In the case where attrition for a continuous outcome is between 0
and 50% and completer-only data are reported, we will reproduce
these.
3.2 Standard deviations
Where there are missing measures of variance for continuous data
but exact standard error and confidence interval are available for
group means, and either P value or T value are available for differ-
ences in mean, we will calculate standard deviation value accord-
ing to method described in Section 7.7.3 of the Cochrane Hand-
book (Higgins 2011). If standard deviations are not reported and
can not be calculated from available data, we will ask authors to
supply the data. In the absence of data from authors, we will use
the mean standard deviation from other studies.
3.3 Last observation carried forward
We anticipate that in some studies the method of last observation
carried forward (LOCF) would be employed within the study
report. As with all methods of imputation to deal with missing
data, LOCF introduces uncertainty about the reliability of the
results. Therefore, where LOCF data has been used in the trial, if
less than50%of the data has been assumed,wewill reproduce these
data and indicate that they are the product of LOCF assumptions.
Assessment of heterogeneity
1. Clinical heterogeneity
To judge clinical heterogeneity, we will consider all included stud-
ies, initially without seeing comparison data. We will simply in-
spect all studies for clearly outlying situations or people which we
had not predicted would arise. Should such situations or partici-
pant groups arise we will fully discuss these.
2. Methodological heterogeneity
Wewill consider all included studies initially, without seeing com-
parison data, to judge methodological heterogeneity.We will sim-
ply inspect all studies for clearly outlying methods which we had
not predicted would arise. Should such methodological outliers
arise we will fully discuss these.
3. Statistical
3.1 Visual inspection
We will visually inspect graphs to investigate the possibility of
statistical heterogeneity.
3.2 Employing the I2 statistic
We will investigate heterogeneity between studies by considering
the I2 method alongside the Chi2 P value. The I2 provides an
estimate of the percentage of inconsistency thought to be due to
chance (Higgins 2003). The importance of the observed value of I
2 depends on i. magnitude and direction of effects and ii. strength
of evidence for heterogeneity (e.g. P value from Chi2 test, or a
confidence interval for I2).
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We will interpret I2 estimate greater than or equal to 50% accom-
panied by a statistically significant Chi2 statistic as evidence of
substantial levels of heterogeneity (Section 9.5.2 - Higgins 2011)
and explore reasons for heterogeneity. If the inconsistency is high
and we find clear reasons, we will present data separately.
Assessment of reporting biases
Reporting biases arise when the dissemination of research findings
is influenced by the nature and direction of results (Egger 1997).
These are described in Section 10 of the Cochrane Handbook (
Higgins 2011). We are aware that funnel plots may be useful in
investigating reporting biases but are of limited power to detect
small-study effects. We will not use funnel plots for outcomes
where there are ten or fewer studies, or where all studies are of
similar sizes. In other cases, where funnel plots are possible, we
will seek statistical advice in their interpretation.
Data synthesis
Where possible we will employ a fixed-effect model for analyses.
We understand that there is no closed argument for preference
for use of fixed-effect or random-effects models. The random-ef-
fects method incorporates an assumption that different studies are
estimating different, yet related, intervention effects. This seems
true. Random-effects methods, however, put added weight onto
the smaller of the studies - those studies that are likely to carry
most bias. This is unfortunate as it seems likely that most studies
we will identify will be small. The fixed-effect model is assump-
tion-free and we favour using this model.
Subgroup analysis and investigation of heterogeneity
1. Subgroup analyses
We anticipate no sub-group analyses.
2. Investigation of heterogeneity
2.1 Unanticipated heterogeneity
Should unanticipated clinical or methodological heterogeneity be
obvious we will simply state hypotheses regarding these for future
reviews or versions of this review.Wedonot anticipate undertaking
analyses relating to these.
2.2 Anticipated heterogeneity
We anticipate some heterogeneity for the primary outcomes, and
propose to summate all data but also present them separately.
Sensitivity analysis
1. Implication of randomisation
We aim to include trials in a sensitivity analysis if they are de-
scribed in some way as to imply randomisation. For the primary
outcomes we will include these studies and if there was no sub-
stantive difference when we added the implied randomised studies
to those with better description of randomisation, we will then
employ all data from these studies.
2. Assumptions for lost binary data
Where assumptions have to be made regarding people lost to fol-
low-up (see Dealing with missing data), we will compare the find-
ings of the primary outcomes where we have used our assumption
and compared with completer data only. If there is a substantial
difference, we will report results and discuss them, but continue
to employ our assumption.
A C K N OW L E D G E M E N T S
Thanks to Professor Clive Adams, Claire Irving, Lindsey Air and
Samantha Roberts and the editorial team at the Nottingham Uni-
versity Cochrane Schizophrenia Group for their unwavering sup-
port in the writing of this protocol. The Cochrane Schizophre-
nia Group Editorial Base in Nottingham produces and maintains
standard text for use in the Methods sections of their reviews. We
have used this text as the basis of what appears here and adapted
it as required.
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